C. Porsbjerg (Copenhagen, Denmark), S. Dortas Junior (Rio De Janeiro (RJ), Brazil)
Onset, Maintenance, and Durability of Response with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps
C. Bachert (Ghent, Belgium), A. Khan (Chilly-Mazarin, France), W. Fokkens (Amsterdam, Netherlands), C. Hopkins (London, United Kingdom), P. Gevaert (Ghent, Belgium), J. Han (Norfolk, United States), P. Hellings (Leuven, Belgium), S. Lee (Boston, United States), J. Msihid (Chilly-Mazarin, France), S. Nash (Tarrytown, United States), S. Siddiqui (Tarrytown, United States), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States)
|   |
Itepekimab significantly reduced hospitalizations or emergency department visits in former smokers with moderate-to-severe COPD
K. Rabe (Grosshansdorf, Kiel, Germany), B. Celli (Boston, United States), A. Praestgaard (Cambridge, United States), M. Djandji (Cambridge, United States), X. Soler (Tarrytown, United States), R. Abdulai (Cambridge, United States), D. Lederer (Tarrytown, United States), H. Goulaouic (Chilly-Mazarin, France), M. Nivens (Tarrytown, United States), S. Siddiqui (Tarrytown, United States), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States)
| |
Impact of obstructive airway diseases (OADs) treatments on adult diphtheria-tetanus-pertussis vaccine (dTap)’s immunogenicity and safety
P. Van den Steen (Wavre, Belgium), V. Berlaimont (Wavre, Belgium), B. Cheuvart (Wavre, Belgium), Q. Deraedt (Wavre, Belgium), L. Valdes Verelst (Wavre, Belgium)
| |
Salivary immunoglobulin E levels in patients treated with Omalizumab
D. Hristova (Sofia, Bulgaria), R. Emilova (Sofia, Bulgaria), Y. Todorova (Sofia, Bulgaria), M. Aleksova (Sofia, Bulgaria), M. Nikolova (Sofia, Bulgaria)
| |
Population PK/PD modelling of the anti-IL-33 antibody tozorakimab to predict pulmonary target engagement in patients with COPD
M. Sadiq (Gothenburg, Sweden), H. Yu (Gaithersburg, United States), M. Astrand (Gothenburg, Sweden), I. Scott (Cambridge, United Kingdom), A. Williams (Cambridge, United Kingdom), L. Hewitt (Gaithersburg, United States), N. White (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), M. Gavala (Gaithersburg, United States), F. Reid (Cambridge, United Kingdom), C. Kell (Cambridge, United Kingdom), H. Pandya (Cambridge, United Kingdom), E. Jimenez (Barcelona, Spain)
| |
The long-term effectiveness of allergy immunotherapy in subjects with asthma is associated with a lower prevalence of sleep disturbances. Results from the REACT-study
M. Contoli (Ferrara, Italy), B. Fritzsching (Heidelberg, Germany), N. Freemantle (London, United Kingdom), S. Buchs (Hoersholm, Denmark), J. Larsen (Hoersholm, Denmark), C. Porsbjerg (Copenhagen, Denmark)
| |
Allergy immunotherapy is associated with a reduced risk of asthma severity progression and lower airway infections. Results from the REACT-study
C. Porsbjerg (Copenhagen, Denmark), B. Fritzsching (Heidelberg, Germany), N. Freemantle (London, United Kingdom), S. Buchs (Hoersholm, Denmark), J. Larsen (Hoersholm, Denmark), M. Contoli (Ferrara, Italy)
| |
Humoral immune responses to COVID-19 vaccines are reduced in patients with severe asthma
H. Rupani (Southampton, United Kingdom), D. Edwards (Southampton, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), S. Smith (Glasgow, United Kingdom), D. Jackson (London, United Kingdom), A. Hearn (London, United Kingdom), J. Richards (Southampton, United Kingdom), H. Moyses (Southampton, United Kingdom), M. Edwards (Londonasgow, United Kingdom), S. Johnston (Londonasgow, United Kingdom), R. Kurukularaaratchy (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), R. Djukanovic (Southampton, United Kingdom)
| |
Efficacy of medical face masks on birch-induced asthma in ALYATEC EEC
A. Gherasim (Strasbourg, France), M. Beck (Strasbourg, France), F. Dietsch (Strasbourg, France), M. Meyer (Strasbourg, France), T. Riff (Strasbourg, France), N. Domis (Strasbourg, France), F. De Blay (Strasbourg, France)
| |
Evaluation of asthma responses in ALYATEC EEC in birch allergic rhinitis (AR) with and without asthma
A. Gherasim (Strasbourg, France), F. Dietsch (Strasbourg, France), M. Beck (Strasbourg, France), T. Riff (Strasbourg, France), N. Domis (Strasbourg, France), F. De Blay (Strasbourg, France)
| |
Beliefs about vaccination and relation to COVID-19 vaccination side-effects in asthma patients.
A. Bossios (Stockholm, Sweden), A. Bacon (Plymouth, United Kingdom), K. Eger (Amsterdam, Netherlands), D. Paróczai (Szeged, Hungary), F. Schleich (Liege, Belgium), S. Hanon (Brussel, Belgium), S. Sergejeva (Tallinn, Estonia), E. Zervas (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), A. Aggelopoulou (Ioannina, Greece), K. Kostikas (Ioannina, Greece), E. Gaki (Ioannina, Greece), N. Rovina (Athens, Greece), Z. Csoma (Budapest, Hungary), I. Grisle (Riga, Latvia), K. Bieksiené (Kaunas, Lithuania), J. Palacionyte (Kaunas, Lithuania), A. Ten Brinke (Leeuwarden, Netherlands), S. Hashimoto (Amsterdam, Netherlands), F. Mihaltan (Bucharest, Romania), N. Nenasheva (Moscow, Russian Federation), B. Zvezdin (Sremska Kamenica, Republic of Serbia), I. Cekerevac (Kragujevac, Republic of Serbia), S. Hromiš (Sremska Kamenica, Republic of Serbia), V. Cupurdija (Kragujevac, Republic of Serbia), Z. Lazic (Kragujevac, Republic of Serbia), R. Chaudhuri (Glasgow, United Kingdom), S. Smith (Glasgow, United Kingdom), H. Rupani (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), O. Fulton (Edinburgh, United Kingdom), B. Frankemölle (Heemskerk, Netherlands), P. Howarth (Middlesex, United Kingdom), C. Porsbjerg (Copenhagen, Denmark), E. Bel (Amsterdam, Netherlands), R. Djukanovic (Southampton, United Kingdom), M. Hyland (Plymouth, United Kingdom)
| |
Efficacy and safety of Phlai capsule for allergic rhinitis: a randomized, double-blind, placebo-controlled study
M. Hoang (Bangkok, Thailand), K. Seresirikachorn (Bangkok, Thailand), S. Kerr (Bangkok, Thailand), J. Kanjanaumporn (Bangkok, Thailand), S. Aeumjaturapat (Bangkok, Thailand), S. Chusakul (Bangkok, Thailand), J. Samuthpongtorn (Bangkok, Thailand), W. Chitsuthipakorn (Bangkok, Thailand), P. Kasemsiri (Khon Kaen, Thailand), V. Kirtsreesakul (Hat Yai, Thailand), K. Prasittivatechakool (Bangkok, Thailand), P. Tantilipikorn (Bangkok, Thailand), O. Poachanukoon (Pathum Thani, Thailand), K. Snidvongs (Bangkok, Thailand)
| |
Effect of dupilumab on asthma control and asthma-related quality of life in patients with uncontrolled, moderate-to-severe type 2 asthma: TRAVERSE OLE study
W. Busse (Madison, United States), I. Pavord (Oxford, United Kingdom), J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), E. Heffler (Milan, Italy), J. Msihid (Chilly-Mazarin, France), S. Siddiqui (Tarrytown, United States), D. Lederer (Tarrytown, United States), M. Hardin (Cambridge, United States), Y. Zhang (Tarrytown, United States), A. Khan (Chilly-Mazarin, France), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States)
| |
Biomarkers associated with lung function decline and dupilumab response in patients with moderate-to-severe asthma
I. Pavord (Oxford, United Kingdom), G. Brusselle (Ghent, Belgium), D. Jackson (Madison, WI, United States), C. Brightling (Leicester, United Kingdom), A. Papi (Ferrara, Italy), J. Maspero (Buenos Aires, Argentina), K. Rabe (Grosshansdorf, Kiel, Germany), S. Korn (Mainz, Germany), M. Zhang (Bridgewater Township, NJ, United States), N. Pandit-Abid (Bridgewater Township, NJ, United States), M. Hardin (Cambridge, MA, United States), L. De Prado Gómez (Reading, United Kingdom), J. Jacob-Nara (Bridgewater Township, NJ, United States), P. Rowe (Bridgewater Township, NJ, United States)
| |
Insilico study of COVID-19 ORF1ab protein allergenicity
F. Hajighasemi (Tehran, Islamic Republic of Iran), A. Shirkavand (Tehran, Islamic Republic of Iran)
| |
Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma
M. Gurnell (Cambridge, United Kingdom), C. Domingo (Barcelona, Spain), K. Rabe (Grosshansdorf, Germany), A. Menzies-Gow (London, United Kingdom), D. Price (Midview City, Singapore), G. Brusselle (Ghent, Belgium), M. Wechsler (Denver, CO, United States), C. Xia (Tarrytown, NY, United States), N. Pandit-Abid (Bridgewater, NJ, United States), R. Gall (Tarrytown, NY, United States), J. Jacob-Nara (Bridgewater, NJ, United States), P. Rowe (Bridgewater, NJ, United States), Y. Deniz (Tarrytown, NY, United States), S. Siddiqui (Tarrytown, NY, United States)
| |
Multidisciplinary checklist approach for the "severe" phenotype: Asthma with Nasal Polyps
J. Castillo Vizuete (Barcelona, Spain), M. Armengot (Valencia, Spain), J. Delgado (Sevilla, Spain), M. Gil (Salamanca, Spain), C. Colás (Zaragoza, Spain), I. Plasencia (Santa Cruz de Tenerife, Spain), C. Cisneros (Madrid, Spain)
| |
One-year treatment with benralizumab in patients with eosinophilic granulomatosis with polyangiitis
P. Scarano (Rome, Italy), C. Cisternino (Rome, Italy), G. Lo Muzio (Rome, Italy), O. Calò (Rome, Italy), A. Sanna (Rome, Italy), A. Steffanina (Rome, Italy), F. De Filippis (Rome, Italy), M. Leporini (Rome, Italy), P. Palange (Rome, Italy), E. Graziani (Rome, Italy)
| |